The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats

Anti-Cancer Drugs

Volumn 8, Issue 7, 1997, Pages 677-685

  Stehle, Gerd ^a,b   Sinn, Hannsjörg ^b   Wunder, Andreas ^a,b   Schrenk, Hans Herrmann ^b   Schütt, Sandra ^a   Maier Borst, Wolfgang ^b   Heene, Dieter Ludwig ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Drug carriers; Methotrexate; Pharmacokinetics; Pharmacology; Residualizing labels; Scavenger receptors; Scintigraphy; Walker 256 carcinosarcoma; 111In DTPA

Indexed keywords

ALBUMIN; ALBUMIN CONJUGATE; BOVINE SERUM ALBUMIN; DRUG CARRIER; FUCOIDIN; METHOTREXATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIVER; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM;

EID: 0030766390     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708000-00006     Document Type: Article

References (45)

1. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997; in press.
2. Peters T. All about albumin: biochemistry, genetics and medical applications. San Diego, CA: Academic Press 1996.
3. Peters T. Serum albumin. Adv Protein Chem 1985; 37: 161-245.
4. Katz G, Bonorris G, Golden S, Sellers AL. Extravascular albumin mass and exchange in rat tissues. Clin Sci 1970; 39: 705-24.
5. Magnenat G, Schindler R, Isliker H. Transport d'agents cytostatiques par les protéines plasmatiques: III. Activité antitumorale in vitro de conjugués cytostatique-azoprotéines. Eur J Cancer 1969; 5: 33-40.
6. Jacobs SA, d'Urso-Scott M, Bertino JR. Some biochemical and pharmacologic properties of amethopterin-albumin. Ann NW Acad Sci 1971; 186: 284-6.
7. Bostik J, Bures L, Spundova M. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. IV. Therapy of murine melanoma B16 by human serum albumin methotrexate derivative. Neoplasma 1988; 35: 343-9.
8. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Radiat Appl Instrum B 1990; 17: 819-27.
9. Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med 1985; 26: 72-6.
10. Butler PJG, Hartley BS. Maleylation of amino groups. Methods Enzymol 1972; 25: 191-9.
11. Imber MJ, Pizzo SV, Johnson WJ, Adams DO. Selective diminution of the binding of mannose by murine macrophages in late stages of activation. J Biol Chem 1982; 257: 5129-35.
12. Ottnad E, Via DP, Frübis J, et al. Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low-density lipoprotein. Biochem J 1992; 281: 745-51.
13. Heinzel G, Woloszczack R, Thomann P. TOPFIT 2.0: Pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer: 1993.
14. Chu BC, Fan CC, Howell SB. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells. J Natl Cancer Inst 1981; 66: 121-4.
15. Chu BC, Howell SB. Differential toxicity of carrier-bound methotrexate toward human lymphocytes, marrow and tumor cells. Biochem Pharmacol 1981; 30: 2545-52.
16. Smyth MJ, Pietersz GA, McKenzie IF. The mode of action of methotrexate-monoclonal antibody conjugates. Immunol Cell Biol 1987; 65: 189-200.
17. Chu BCF, Whiteley JM. High molecular weight derivatives of methotrexate as chemotherapeutic agents. Mol Pharmacol 1976; 13: 80-8.
18. Shen WC, Ryser HJ. Selective killing of Fc-receptor-bearing tumor cells through endocytosis of a drug-carrying immune complex. Proc Natl Acad Sci USA 1984; 81: 1445-7.
19. Halbert GW, Florence AT, Stuart JF. Characterization of in-vitro drug release and biological activity of methotrexate-bovine serum albumin conjugates. J Pharm Pharmacol 1987; 39: 871-6.
20. Bures L, Bostik J, Motycka K, Spundova M, Rehak L. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin methotrexate derivative, its preparation and basic testing. Neoplasma 1988; 35: 329-42.
21. Bures L, Lichy A, Bostik J, Spundova M. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin methotrexate derivative. Neoplasma 1990; 37: 225-31.
22. Kim CK, Hwang SJ, Lee MG. The organ targetability of small and large albumin microspheres containing free and USA conjugated methotrexate. Int J Pharm 1993; 89: 91-102.
23. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for the studies of protein catabolism. FASEB J 1993; 7: 399-405.
24. Lucas KL, Baynes JW, Thorpe SR. Intracellular processing of residualizing labels in different cell types in vitro. J Cell Physiol 1990; 142: 581-5.
25. Tassin MT, Lang T, Antoine JC, Hellio R, Ryter A. Modified lysosomal compartment as carrier of slowly and non-degradable tracers in macrophages. Eur J Cell Biol 1990; 52: 219-28.
26. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 1995; 55: 5714s-20s.
27. Arano Y, Mukai T, Akizawa H, et al. Radiolabeled metabolites of proteins play a critical role in radioactivity elimination from the liver. Nucl Med Biol 1995; 22: 555-64.
28. Halbert GW, Florence AT. Physiochemical characterization of methotrexate-bovine serum albumin conjugates. J Pharm Pharmacol 1989; 41: 222-6.
29. Timkovich R. Polymerisation side reactions during protein modifications with carbodiimide. Biochim Biophys Acta 1977; 74: 1463-8.
30. Hampton RY, Golenbock DT, Penman M, Krieger M, Raetz CR. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 1991; 352: 342-4.
31. Acton S, Resnick D, Freeman M, Ekkel Y, Ashkenas J, Krieger M. The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J Biol Chem 1993; 268: 3530-7.
32. Krieger M, Acton S, Ashkenas J, Pearson A, Penman M, Resnick D. Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J Biol Chem 1993; 268: 4569-72.
33. Takata K, Horiuchi S, Morino Y. Scavenger receptor-mediated recognition of maleylated albumin and its relation to subsequent endocytic degradation. Biochim Biophys Acta 1989; 984: 273-80.
34. Haberland ME, Tannenbaum CS, Williams RE, Adams DO, Hamilton TA. Role of the maleyl-albumin receptor in activation of murine peritoneal macrophages in vitro. J Immunol 1989; 142: 855-62.
35. Zhang H, Yang Y, Steinbrecher UP. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J Biol Chem 1993; 268: 5535-42.
36. Stehle G, Friedrich EA, Sinn H, et al. Hepatic uptake of a modified low molecular weight heparin in the rat. J Clin Invest 1992; 90: 2110-6.
37. Stehle G, Wunder A, Sinn H, et al. Complexes of a modified low molecular weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor mediated process in rats. J Surg Res 1995; 58: 197-204.
38. Wunder A, Stehle G, Sinn H, et al. The injection of heparin prolongs plasma clearance of oxidized low density lipoprotein in the rat. Thromb Res 1995; 78: 139-49.
39. Franssen EJ, Jansen RW, Vaalburg M, Meijer DK. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem Pharmacol 1993; 45: 1215-26.
40. Abraham R, Singh N, Mukhopadhyay A, Basu SK, Bal V, Rath S. Modulation of immunogenicity and antigenicity of proteins by maleylation to target scavenger receptors on macrophages. J Immunol 1995; 154: 1-8.
41. Stehle G, Sinn H, Wunder A, et al. Albumin catabolism by tumors. ECCO 9 1997; A 795 (abstr).
42. Stehle G, Sinn H, Wunder A, et al. Tumor uptake of MTX-albumin conjugates in rats. ECCO 9 1997; A 808 (abstr).
43. Wunder A, Stehle G, Sinn H, et al. Radiokinetics of MTX-albumin conjugates in rats. ECCO 9 1997; A 794 (abstr).
44. Wunder A, Stehle G, Sinn H, et al. Antitumor activity of MTX-HSA conjugates in rats. ECCO 9 1997; A 800 (abstr).
45. Hartung G, Stehle G, Sinn H, et al. Phase-1 trial of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients. ECCO 9 1997; 1129 (abstr).